Tumor angiogenesis: MMP-mediated induction of intravasation- and metastasis-sustaining neovasculature

Matrix Biology

Volumn 44-46, Issue , 2015, Pages 94-112

  Deryugina, Elena I ^a   Quigley, James P ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

Epidermal growth factor receptor; Matrix metalloproteinase; Tissue inhibitor of metalloproteinases; Tumor angiogenesis; Tumor cell intravasation and metastasis; Tumor associated macrophages; Tumor associated neutrophils; Vascular endothelial growth factor

Indexed keywords

GELATINASE B; INTERSTITIAL COLLAGENASE; MATRIX METALLOPROTEINASE; VASCULOTROPIN; VASCULOTROPIN A;

BIOAVAILABILITY; CANCER ASSOCIATED FIBROBLAST; CANCER CELL; CANCER GROWTH; CELL INFILTRATION; FIBROBLAST; HUMAN; INFLAMMATORY CELL; MACROPHAGE; METASTASIS; NEOVASCULARIZATION (PATHOLOGY); NEUTROPHIL; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PERICYTE; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; TISSUE STRUCTURE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR BLOOD FLOW; TUMOR CELL; TUMOR PROMOTION; TUMOR VASCULARIZATION; ANIMAL; ENZYMOLOGY; METABOLISM; NEOPLASM; PATHOLOGY; VASCULARIZATION;

ANIMALS; HUMANS; MATRIX METALLOPROTEINASES; NEOPLASM METASTASIS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84930764392     PISSN: 0945053X     EISSN: 15691802     Source Type: Journal    
DOI: 10.1016/j.matbio.2015.04.004     Document Type: Review

References (185)

1. Al Rawashdeh W., Arns S., Gremse F., Ehling J., Knuchel-Clarke R., Kray S., et al. Optical tomography of MMP activity allows a sensitive noninvasive characterization of the invasiveness and angiogenesis of SCC xenografts. Neoplasia 2014, 16:235-246. (246 e1).
2. Ardi V.C., Kupriyanova T.A., Deryugina E.I., Quigley J.P. Human neutrophils uniquely release TIMP-free MMP-9 to provide a potent catalytic stimulator of angiogenesis. Proc Natl Acad Sci U S A 2007, 104:20262-20267. (PCMID2154419).
3. Ardi V.C., Van den Steen P.E., Opdenakker G., Schweighofer B., Deryugina E.I., Quigley J.P. Neutrophil MMP-9 proenzyme, unencumbered by TIMP-1, undergoes efficient activation in vivo and catalytically induces angiogenesis via a basic fibroblast growth factor (FGF-2)/FGFR-2 pathway. J Biol Chem 2009, 284:25854-25866. (PCMID2757987).
4. Bar-Or A., Nuttall R.K., Duddy M., Alter A., Kim H.J., Ifergan I., et al. Analyses of all matrix metalloproteinase members in leukocytes emphasize monocytes as major inflammatory mediators in multiple sclerosis. Brain 2003, 126:2738-2749.
5. Barillari G., Iovane A., Bacigalupo I., Labbaye C., Chiozzini C., Sernicola L., et al. The HIV protease inhibitor indinavir down-regulates the expression of the pro-angiogenic MT1-MMP by human endothelial cells. Angiogenesis 2014, 17:831-838.
6. Bausch D., Pausch T., Krauss T., Hopt U.T., Fernandez-del-Castillo C., Warshaw A.L., et al. Neutrophil granulocyte derived MMP-9 is a VEGF independent functional component of the angiogenic switch in pancreatic ductal adenocarcinoma. Angiogenesis 2011, 14:235-243.
7. Bekes E.M., Deryugina E.I., Kupriyanova T.A., Zajac E., Botkjaer K.A., Andreasen P.A., et al. Activation of pro-uPA is critical for initial escape from the primary tumor and hematogenous dissemination of human carcinoma cells. Neoplasia 2011, 13:806-821.
8. Bekes E.M., Schweighofer B., Kupriyanova T.A., Zajac E., Ardi V.C., Quigley J.P., et al. Tumor-recruited neutrophils and neutrophil TIMP-free MMP-9 regulate coordinately the levels of tumor angiogenesis and efficiency of malignant cell intravasation. Am J Pathol 2011, 179:1455-1470.
9. Belotti D., Calcagno C., Garofalo A., Caronia D., Riccardi E., Giavazzi R., et al. Vascular endothelial growth factor stimulates organ-specific host matrix metalloproteinase-9 expression and ovarian cancer invasion. Mol Cancer Res 2008, 6:525-534.
10. Belotti D., Paganoni P., Manenti L., Garofalo A., Marchini S., Taraboletti G., et al. Matrix metalloproteinases (MMP9 and MMP2) induce the release of vascular endothelial growth factor (VEGF) by ovarian carcinoma cells: implications for ascites formation. Cancer Res 2003, 63:5224-5229.
11. Benelli R., Morini M., Carrozzino F., Ferrari N., Minghelli S., Santi L., et al. Neutrophils as a key cellular target for angiostatin: implications for regulation of angiogenesis and inflammation. FASEB J 2002, 16:267-269.
12. Bergers G., Brekken R., McMahon G., Vu T.H., Itoh T., Tamaki K., et al. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2000, 2:737-744.
13. Bergers G., Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 2008, 8:592-603.
14. Bhoopathi P., Chetty C., Gujrati M., Dinh D.H., Rao J.S., Lakka S.S. The role of MMP-9 in the anti-angiogenic effect of secreted protein acidic and rich in cysteine. Br J Cancer 2010, 102:530-540.
15. Bjorklund M., Koivunen E. Gelatinase-mediated migration and invasion of cancer cells. Biochim Biophys Acta 2005, 1755:37-69.
16. Boire A., Covic L., Agarwal A., Jacques S., Sherifi S., Kuliopulos A. PAR1 is a matrix metalloprotease-1 receptor that promotes invasion and tumorigenesis of breast cancer cells. Cell 2005, 120:303-313.
17. Brat D.J., Bellail A.C., Van Meir E.G. The role of interleukin-8 and its receptors in gliomagenesis and tumoral angiogenesis. Neuro Oncol 2005, 7:122-133.
18. Brinckerhoff C.E., Rutter J.L., Benbow U. Interstitial collagenases as markers of tumor progression. Clin Cancer Res 2000, 6:4823-4830.
19. Bruni-Cardoso A., Johnson L.C., Vessella R.L., Peterson T.E., Lynch C.C. Osteoclast-derived matrix metalloproteinase-9 directly affects angiogenesis in the prostate tumor-bone microenvironment. Mol Cancer Res 2010, 8:459-470.
20. Byrne A.T., Ross L., Holash J., Nakanishi M., Hu L., Hofmann J.I., et al. Vascular endothelial growth factor-trap decreases tumor burden, inhibits ascites, and causes dramatic vascular remodeling in an ovarian cancer model. Clin Cancer Res 2003, 9:5721-5728.
21. Carmeliet P., Jain R.K. Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases. Nat Rev Drug Discov 2011, 10:417-427.
22. Casazza A., Laoui D., Wenes M., Rizzolio S., Bassani N., Mambretti M., et al. Impeding macrophage entry into hypoxic tumor areas by Sema3A/Nrp1 signaling blockade inhibits angiogenesis and restores antitumor immunity. Cancer Cell 2013, 24:695-709.
23. Cerniglia G.J., Pore N., Tsai J.H., Schultz S., Mick R., Choe R., et al. Epidermal growth factor receptor inhibition modulates the microenvironment by vascular normalization to improve chemotherapy and radiotherapy efficacy. PLoS ONE 2009, 4. e6539.
24. Chantrain C.F., Henriet P., Jodele S., Emonard H., Feron O., Courtoy P.J., et al. Mechanisms of pericyte recruitment in tumour angiogenesis: a new role for metalloproteinases. Eur J Cancer 2006, 42:310-318.
25. Chantrain C.F., Shimada H., Jodele S., Groshen S., Ye W., Shalinsky D.R., et al. Stromal matrix metalloproteinase-9 regulates the vascular architecture in neuroblastoma by promoting pericyte recruitment. Cancer Res 2004, 64:1675-1686.
26. Chetty C., Lakka S.S., Bhoopathi P., Rao J.S. MMP-2 alters VEGF expression via alphaVbeta3 integrin-mediated PI3K/AKT signaling in A549 lung cancer cells. Int J Cancer 2010, 127:1081-1095.
27. Choe G., Park J.K., Jouben-Steele L., Kremen T.J., Liau L.M., Vinters H.V., et al. Active matrix metalloproteinase 9 expression is associated with primary glioblastoma subtype. Clin Cancer Res 2002, 8:2894-2901.
28. Chung A.S., Ferrara N. Developmental and pathological angiogenesis. Annu Rev Cell Dev Biol 2011, 27:563-584.
29. Claes A., Wesseling P., Jeuken J., Maass C., Heerschap A., Leenders W.P. Antiangiogenic compounds interfere with chemotherapy of brain tumors due to vessel normalization. Mol Cancer Ther 2008, 7:71-78.
30. Coffelt S.B., Lewis C.E., Naldini L., Brown J.M., Ferrara N., De Palma M. Elusive identities and overlapping phenotypes of proangiogenic myeloid cells in tumors. Am J Pathol 2010, 176:1564-1576.
31. Coffelt S.B., Tal A.O., Scholz A., De Palma M., Patel S., Urbich C., et al. Angiopoietin-2 regulates gene expression in TIE2-expressing monocytes and augments their inherent proangiogenic functions. Cancer Res 2010, 70:5270-5280.
32. Coussens L.M., Raymond W.W., Bergers G., Laig-Webster M., Behrendtsen O., Werb Z., et al. Inflammatory mast cells up-regulate angiogenesis during squamous epithelial carcinogenesis. Genes Dev 1999, 13:1382-1397.
33. Crawford Y., Ferrara N. Chapter 6. Mouse models to investigate anti-cancer effects of VEGF inhibitors. Methods Enzymol 2008, 445:125-139.
34. Curry J.M., Sprandio J., Cognetti D., Luginbuhl A., Bar-ad V., Pribitkin E., et al. Tumor microenvironment in head and neck squamous cell carcinoma. Semin Oncol 2014, 41:217-234.
35. Dalton H.J., Armaiz-Pena G.N., Gonzalez-Villasana V., Lopez-Berestein G., Bar-Eli M., Sood A.K. Monocyte subpopulations in angiogenesis. Cancer Res 2014, 74:1287-1293.
36. Dawson M.R., Duda D.G., Fukumura D., Jain R.K. VEGFR1-activity-independent metastasis formation. Nature 2009, 461. (E4; discussion E5).
37. De Bock K., Cauwenberghs S., Carmeliet P. Vessel abnormalization: another hallmark of cancer? Molecular mechanisms and therapeutic implications. Curr Opin Genet Dev 2011, 21:73-79.
38. De Francesco E.M., Lappano R., Santolla M.F., Marsico S., Caruso A., Maggiolini M. HIF-1alpha/GPER signaling mediates the expression of VEGF induced by hypoxia in breast cancer associated fibroblasts (CAFs). Breast Cancer Res 2013, 15:R64.
39. De Larco J.E., Wuertz B.R., Furcht L.T. The potential role of neutrophils in promoting the metastatic phenotype of tumors releasing interleukin-8. Clin Cancer Res 2004, 10:4895-4900.
40. Depner S., Lederle W., Gutschalk C., Linde N., Zajonz A., Mueller M.M. Cell type specific interleukin-6 induced responses in tumor keratinocytes and stromal fibroblasts are essential for invasive growth. Int J Cancer 2014, 135:551-562.
41. Deryugina E.I. Chorioallantoic membrane microtumor model to study the mechanisms of tumor angiogenesis, vascular permeability and tumor cell intravasation. Angiogenesis 2015, (in press). S.G. Martin, P. Hewett (Eds.).
42. Deryugina E.I., Quigley J.P. Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev 2006, 25:9-34.
43. Deryugina E.I., Soroceanu L., Strongin A.Y. Up-regulation of vascular endothelial growth factor by membrane-type 1 matrix metalloproteinase stimulates human glioma xenograft growth and angiogenesis. Cancer Res 2002, 62:580-588.
44. Deryugina E.I., Zajac E., Juncker-Jensen A., Kupriyanova T.A., Welter L., Quigley J.P. Tissue-infiltrating neutrophils constitute the major in vivo source of angiogenesis-inducing mmp-9 in the tumor microenvironment. Neoplasia 2014, 16:771-788.
45. Deryugina E.I., Zijlstra A., Partridge J.J., Kupriyanova T.A., Madsen M.A., Papagiannakopoulos T., et al. Unexpected effect of matrix metalloproteinase down-regulation on vascular intravasation and metastasis of human fibrosarcoma cells selected in vivo for high rates of dissemination. Cancer Res 2005, 65:10959-10969.
46. Dondossola E., Rangel R., Guzman-Rojas L., Barbu E.M., Hosoya H., John St, et al. CD13-positive bone marrow-derived myeloid cells promote angiogenesis, tumor growth, and metastasis. Proc Natl Acad Sci U S A 2013, 110:20717-20722.
47. Du R., Lu K.V., Petritsch C., Liu P., Ganss R., Passegue E., et al. HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion. Cancer Cell 2008, 13:206-220.
48. Du R., Petritsch C., Lu K., Liu P., Haller A., Ganss R., et al. Matrix metalloproteinase-2 regulates vascular patterning and growth affecting tumor cell survival and invasion in GBM. Neuro Oncol 2008, 10:254-264.
49. Dumitru C.A., Moses K., Trellakis S., Lang S., Brandau S. Neutrophils and granulocytic myeloid-derived suppressor cells: immunophenotyping, cell biology and clinical relevance in human oncology. Cancer Immunol Immunother 2012, 61:1155-1167.
50. Ebos J.M., Lee C.R., Cruz-Munoz W., Bjarnason G.A., Christensen J.G., Kerbel R.S. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 2009, 15:232-239.
51. Ebrahem Q., Chaurasia S.S., Vasanji A., Qi J.H., Klenotic P.A., Cutler A., et al. Cross-talk between vascular endothelial growth factor and matrix metalloproteinases in the induction of neovascularization in vivo. Am J Pathol 2010, 176:496-503.
52. Egeblad M., Nakasone E.S., Werb Z. Tumors as organs: complex tissues that interface with the entire organism. Dev Cell 2010, 18:884-901.
53. Ellerbroek S.M., Halbleib J.M., Benavidez M., Warmka J.K., Wattenberg E.V., Stack M.S., et al. Phosphatidylinositol 3-kinase activity in epidermal growth factor-stimulated matrix metalloproteinase-9 production and cell surface association. Cancer Res 2001, 61:1855-1861.
54. Ellis L.M., Hicklin D.J. VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer 2008, 8:579-591.
55. Elpek K.G., Cremasco V., Shen H., Harvey C.J., Wucherpfennig K.W., Goldstein D.R., et al. The tumor microenvironment shapes lineage, transcriptional, and functional diversity of infiltrating myeloid cells. Cancer Immunol Res 2014, 2:655-667.
56. Erez N., Coussens L.M. Leukocytes as paracrine regulators of metastasis and determinants of organ-specific colonization. Int J Cancer 2011, 128:2536-2544.
57. Farina A.R., Mackay A.R. Gelatinase B/MMP-9 in tumour pathogenesis and progression. Cancers (Basel) 2014, 6:240-296.
58. Ferrara N., Gerber H.P., LeCouter J. The biology of VEGF and its receptors. Nat Med 2003, 9:669-676.
59. Fleming T.J., Fleming M.L., Malek T.R. Selective expression of Ly-6G on myeloid lineage cells in mouse bone marrow. RB6-8C5 mAb to granulocyte-differentiation antigen (Gr-1) detects members of the Ly-6 family. J Immunol 1993, 151:2399-2408.
60. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971, 285:1182-1186.
61. Folkman J., Watson K., Ingber D., Hanahan D. Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 1989, 339:58-61.
62. Fridlender Z.G., Sun J., Kim S., Kapoor V., Cheng G., Ling L., et al. Polarization of tumor-associated neutrophil phenotype by TGF-beta: "N1" versus "N2" TAN. Cancer Cell 2009, 16:183-194.
63. Galdiero M.R., Garlanda C., Jaillon S., Marone G., Mantovani A. Tumor associated macrophages and neutrophils in tumor progression. J Cell Physiol 2013, 228:1404-1412.
64. Garcia-Roman J., Zentella-Dehesa A. Vascular permeability changes involved in tumor metastasis. Cancer Lett 2013, 335:259-269.
65. Garmy-Susini B., Avraamides C.J., Schmid M.C., Foubert P., Ellies L.G., Barnes L., et al. Integrin alpha4beta1 signaling is required for lymphangiogenesis and tumor metastasis. Cancer Res 2010, 70:3042-3051.
66. Giraudo E., Inoue M., Hanahan D. An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis. J Clin Invest 2004, 114:623-633.
67. Goel H.L., Mercurio A.M. VEGF targets the tumour cell. Nat Rev Cancer 2013, 13:871-882.
68. Goel S., Duda D.G., Xu L., Munn L.L., Boucher Y., Fukumura D., et al. Normalization of the vasculature for treatment of cancer and other diseases. Physiol Rev 2011, 91:1071-1121.
69. Gong Y., Chippada-Venkata U.D., Oh W.K. Roles of matrix metalloproteinases and their natural inhibitors in prostate cancer progression. Cancers (Basel) 2014, 6:1298-1327.
70. Gong Y., Hart E., Shchurin A., Hoover-Plow J. Inflammatory macrophage migration requires MMP-9 activation by plasminogen in mice. J Clin Invest 2008, 118:3012-3024.
71. Green C.E., Liu T., Montel V., Hsiao G., Lester R.D., Subramaniam S., et al. Chemoattractant signaling between tumor cells and macrophages regulates cancer cell migration, metastasis and neovascularization. PLoS ONE 2009, 4. e6713.
72. Greenberg J.I., Shields D.J., Barillas S.G., Acevedo L.M., Murphy E., Huang J., et al. A role for VEGF as a negative regulator of pericyte function and vessel maturation. Nature 2008, 456:809-813.
73. Gregory A.D., McGarry Houghton A. Tumor-associated neutrophils: new targets for cancer therapy. Cancer Res 2011, 71:2411-2416.
74. Grivennikov S.I., Greten F.R., Karin M. Immunity, inflammation, and cancer. Cell 2010, 140:883-899.
75. Halin S., Rudolfsson S.H., Van Rooijen N., Bergh A. Extratumoral macrophages promote tumor and vascular growth in an orthotopic rat prostate tumor model. Neoplasia 2009, 11:177-186.
76. Hanahan D., Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996, 86:353-364.
77. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell 2000, 100:57-70.
78. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
79. Hao Q., Chen Y., Zhu Y., Fan Y., Palmer D., Su H., et al. Neutrophil depletion decreases VEGF-induced focal angiogenesis in the mature mouse brain. J Cereb Blood Flow Metab 2007, 27:1853-1860.
80. Haqqani A.S., Sandhu J.K., Birnboim H.C. Expression of interleukin-8 promotes neutrophil infiltration and genetic instability in mutatect tumors. Neoplasia 2000, 2:561-568.
81. Hashimoto G., Inoki I., Fujii Y., Aoki T., Ikeda E., Okada Y. Matrix metalloproteinases cleave connective tissue growth factor and reactivate angiogenic activity of vascular endothelial growth factor 165. J Biol Chem 2002, 277:36288-36295.
82. Hawinkels L.J., Zuidwijk K., Verspaget H.W., de Jonge-Muller E.S., van Duijn W., Ferreira V., et al. VEGF release by MMP-9 mediated heparan sulphate cleavage induces colorectal cancer angiogenesis. Eur J Cancer 2008, 44:1904-1913.
83. Hiratsuka S., Nakamura K., Iwai S., Murakami M., Itoh T., Kijima H., et al. MMP9 induction by vascular endothelial growth factor receptor-1 is involved in lung-specific metastasis. Cancer Cell 2002, 2:289-300.
84. Hoeben A., Landuyt B., Highley M.S., Wildiers H., Van Oosterom A.T., De Bruijn E.A. Vascular endothelial growth factor and angiogenesis. Pharmacol Rev 2004, 56:549-580.
85. Houck K.A., Leung D.W., Rowland A.M., Winer J., Ferrara N. Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms. J Biol Chem 1992, 267:26031-26037.
86. Houghton A.M. The paradox of tumor-associated neutrophils: fueling tumor growth with cytotoxic substances. Cell Cycle 2010, 9. (Epub ahead of print).
87. Huang J., Frischer J.S., Serur A., Kadenhe A., Yokoi A., McCrudden K.W., et al. Regression of established tumors and metastases by potent vascular endothelial growth factor blockade. Proc Natl Acad Sci U S A 2003, 100:7785-7790.
88. Huang S., Van Arsdall M., Tedjarati S., McCarty M., Wu W., Langley R., et al. Contributions of stromal metalloproteinase-9 to angiogenesis and growth of human ovarian carcinoma in mice. J Natl Cancer Inst 2002, 94:1134-1142.
89. Huss W.J., Hanrahan C.F., Barrios R.J., Simons J.W., Greenberg N.M. Angiogenesis and prostate cancer: identification of a molecular progression switch. Cancer Res 2001, 61:2736-2743.
90. Hwang Y.P., Yun H.J., Choi J.H., Han E.H., Kim H.G., Song G.Y., et al. Suppression of EGF-induced tumor cell migration and matrix metalloproteinase-9 expression by capsaicin via the inhibition of EGFR-mediated FAK/Akt, PKC/Raf/ERK, p38 MAPK, and AP-1 signaling. Mol Nutr Food Res 2011, 55:594-605.
91. Ito T.K., Ishii G., Chiba H., Ochiai A. The VEGF angiogenic switch of fibroblasts is regulated by MMP-7 from cancer cells. Oncogene 2007, 26:7194-7203.
92. Jablonska J., Leschner S., Westphal K., Lienenklaus S., Weiss S. Neutrophils responsive to endogenous IFN-beta regulate tumor angiogenesis and growth in a mouse tumor model. J Clin Invest 2010, 120:1151-1164.
93. Jain R.K. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005, 307:58-62.
94. Jodele S., Chantrain C.F., Blavier L., Lutzko C., Crooks G.M., Shimada H., et al. The contribution of bone marrow-derived cells to the tumor vasculature in neuroblastoma is matrix metalloproteinase-9 dependent. Cancer Res 2005, 65:3200-3208.
95. Juncker-Jensen A., Deryugina E.I., Rimann I., Zajac E., Kupriyanova T.A., Engelholm L.H., et al. Tumor MMP-1 activates endothelial PAR1 to facilitate vascular intravasation and metastatic dissemination. Cancer Res 2013, 73:4196-4211.
96. Kahlert C., Pecqueux M., Halama N., Dienemann H., Muley T., Pfannschmidt J., et al. Tumour-site-dependent expression profile of angiogenic factors in tumour-associated stroma of primary colorectal cancer and metastases. Br J Cancer 2014, 110:441-449.
97. Kaimal R., Aljumaily R., Tressel S.L., Pradhan R.V., Covic L., Kuliopulos A., et al. Selective blockade of matrix metalloprotease-14 with a monoclonal antibody abrogates invasion, angiogenesis, and tumor growth in ovarian cancer. Cancer Res 2013, 73:2457-2467.
98. Kanai T., Konno H., Tanaka T., Baba M., Matsumoto K., Nakamura S., et al. Anti-tumor and anti-metastatic effects of human-vascular-endothelial-growth-factor-neutralizing antibody on human colon and gastric carcinoma xenotransplanted orthotopically into nude mice. Int J Cancer 1998, 77:933-936.
99. Kim J., Thorne S.H., Sun L., Huang B., Mochly-Rosen D. Sustained inhibition of PKCalpha reduces intravasation and lung seeding during mammary tumor metastasis in an in vivo mouse model. Oncogene 2011, 30:323-333.
100. Kim S., Choi J.H., Lim H.I., Lee S.K., Kim W.W., Cho S., et al. EGF-induced MMP-9 expression is mediated by the JAK3/ERK pathway, but not by the JAK3/STAT-3 pathway in a SKBR3 breast cancer cell line. Cell Signal 2009, 21:892-898.
101. Kim S.J., Uehara H., Karashima T., McCarty M., Shih N., Fidler I.J. Expression of interleukin-8 correlates with angiogenesis, tumorigenicity, and metastasis of human prostate cancer cells implanted orthotopically in nude mice. Neoplasia 2001, 3:33-42.
102. Kiriakidis S., Andreakos E., Monaco C., Foxwell B., Feldmann M., Paleolog E. VEGF expression in human macrophages is NF-kappaB-dependent: studies using adenoviruses expressing the endogenous NF-kappaB inhibitor IkappaBalpha and a kinase-defective form of the IkappaB kinase 2. J Cell Sci 2003, 116:665-674.
103. Kuang D.M., Zhao Q., Wu Y., Peng C., Wang J., Xu Z., et al. Peritumoral neutrophils link inflammatory response to disease progression by fostering angiogenesis in hepatocellular carcinoma. J Hepatol 2011, 54:948-955.
104. Kudo Y., Iizuka S., Yoshida M., Tsunematsu T., Kondo T., Subarnbhesaj A., et al. Matrix metalloproteinase-13 (MMP-13) directly and indirectly promotes tumor angiogenesis. J Biol Chem 2012, 287:38716-38728.
105. Lawrence T., Natoli G. Transcriptional regulation of macrophage polarization: enabling diversity with identity. Nat Rev Immunol 2011, 11:750-761.
106. Lederle W., Hartenstein B., Meides A., Kunzelmann H., Werb Z., Angel P., et al. MMP13 as a stromal mediator in controlling persistent angiogenesis in skin carcinoma. Carcinogenesis 2010, 31:1175-1184.
107. Lee S., Jilani S.M., Nikolova G.V., Carpizo D., Iruela-Arispe M.L. Processing of VEGF-A by matrix metalloproteinases regulates bioavailability and vascular patterning in tumors. J Cell Biol 2005, 169:681-691.
108. Leifler K.S., Svensson S., Abrahamsson A., Bendrik C., Robertson J., Gauldie J., et al. Inflammation induced by MMP-9 enhances tumor regression of experimental breast cancer. J Immunol 2013, 190:4420-4430.
109. Liao D., Johnson R.S. Hypoxia: a key regulator of angiogenesis in cancer. Cancer Metastasis Rev 2007, 26:281-290.
110. Loges S., Mazzone M., Hohensinner P., Carmeliet P. Silencing or fueling metastasis with VEGF inhibitors: antiangiogenesis revisited. Cancer Cell 2009, 15:167-170.
111. Lovett R.W., Councilman W.T. A case of double teratoma. J Exp Med 1897, 2:427-438.
112. Mancuso M.R., Davis R., Norberg S.M., O'Brien S., Sennino B., Nakahara T., et al. Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J Clin Invest 2006, 116:2610-2621.
113. Mantovani A., Cassatella M.A., Costantini C., Jaillon S. Neutrophils in the activation and regulation of innate and adaptive immunity. Nat Rev Immunol 2011, 11:519-531.
114. Mazor R., Alsaigh T., Shaked H., Altshuler A.E., Pocock E.S., Kistler E.B., et al. Matrix metalloproteinase-1-mediated up-regulation of vascular endothelial growth factor-2 in endothelial cells. J Biol Chem 2013, 288:598-607.
115. Mazzone M., Dettori D., Leite de Oliveira R., Loges S., Schmidt T., Jonckx B., et al. Heterozygous deficiency of PHD2 restores tumor oxygenation and inhibits metastasis via endothelial normalization. Cell 2009, 136:839-851.
116. Mira E., Lacalle R.A., Buesa J.M., de Buitrago G.G., Jimenez-Baranda S., Gomez-Mouton C., et al. Secreted MMP9 promotes angiogenesis more efficiently than constitutive active MMP9 bound to the tumor cell surface. J Cell Sci 2004, 117:1847-1857.
117. Mitra S.K., Schlaepfer D.D. Integrin-regulated FAK-Src signaling in normal and cancer cells. Curr Opin Cell Biol 2006, 18:516-523.
118. Normanno N., Gullick W.J. Epidermal growth factor receptor tyrosine kinase inhibitors and bone metastases: different mechanisms of action for a novel therapeutic application?. Endocr Relat Cancer 2006, 13:3-6.
119. Nozawa H., Chiu C., Hanahan D. Infiltrating neutrophils mediate the initial angiogenic switch in a mouse model of multistage carcinogenesis. Proc Natl Acad Sci U S A 2006, 103:12493-12498.
120. O'Connell J.T., Sugimoto H., Cooke V.G., MacDonald B.A., Mehta A.I., LeBleu V.S., et al. VEGF-A and Tenascin-C produced by S100A4+ stromal cells are important for metastatic colonization. Proc Natl Acad Sci U S A 2011, 108:16002-16007.
121. O-Charoenrat P., Modjtahedi H., Rhys-Evans P., Court W.J., Box G.M., Eccles S.A. Epidermal growth factor-like ligands differentially up-regulate matrix metalloproteinase 9 in head and neck squamous carcinoma cells. Cancer Res 2000, 60:1121-1128.
122. Ogata Y., Itoh Y., Nagase H. Steps involved in activation of the pro-matrix metalloproteinase 9 (progelatinase B)-tissue inhibitor of metalloproteinases-1 complex by 4-aminophenylmercuric acetate and proteinases. J Biol Chem 1995, 270:18506-18511.
123. Okada Y., Gonoji Y., Naka K., Tomita K., Nakanishi I., Iwata K., et al. Matrix metalloproteinase 9 (92-kDa gelatinase/type IV collagenase) from HT 1080 human fibrosarcoma cells. Purification and activation of the precursor and enzymic properties. J Biol Chem 1992, 267:21712-21719.
124. Owen C.A., Campbell E.J. The cell biology of leukocyte-mediated proteolysis. J Leukoc Biol 1999, 65:137-150.
125. Owen J.L., Iragavarapu-Charyulu V., Gunja-Smith Z., Herbert L.M., Grosso J.F., Lopez D.M. Up-regulation of matrix metalloproteinase-9 in T lymphocytes of mammary tumor bearers: role of vascular endothelial growth factor. J Immunol 2003, 171:4340-4351.
126. Paez-Ribes M., Allen E., Hudock J., Takeda T., Okuyama H., Vinals F., et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009, 15:220-231.
127. Pahler J.C., Tazzyman S., Erez N., Chen Y.Y., Murdoch C., Nozawa H., et al. Plasticity in tumor-promoting inflammation: impairment of macrophage recruitment evokes a compensatory neutrophil response. Neoplasia 2008, 10:329-340.
128. Parsons-Wingerter P., Chandrasekharan U.M., McKay T.L., Radhakrishnan K., DiCorleto P.E., Albarran B., et al. A VEGF165-induced phenotypic switch from increased vessel density to increased vessel diameter and increased endothelial NOS activity. Microvasc Res 2006, 72:91-100.
129. Partridge J.J., Madsen M.A., Ardi V.C., Papagiannakopoulos T., Kupriyanova T.A., Quigley J.P., et al. Functional analysis of matrix metalloproteinases and tissue inhibitors of metalloproteinases differentially expressed by variants of human HT-1080 fibrosarcoma exhibiting high and low levels of intravasation and metastasis. J Biol Chem 2007, 282:35964-35977.
130. Pekarek L.A., Starr B.A., Toledano A.Y., Schreiber H. Inhibition of tumor growth by elimination of granulocytes. J Exp Med 1995, 181:435-440.
131. Piccard H., Muschel R.J., Opdenakker G. On the dual roles and polarized phenotypes of neutrophils in tumor development and progression. Crit Rev Oncol Hematol 2012, 82:296-309.
132. Pore N., Jiang Z., Gupta A., Cerniglia G., Kao G.D., Maity A. EGFR tyrosine kinase inhibitors decrease VEGF expression by both hypoxia-inducible factor (HIF)-1-independent and HIF-1-dependent mechanisms. Cancer Res 2006, 66:3197-3204.
133. Qian B., Deng Y., Im J.H., Muschel R.J., Zou Y., Li J., et al. A distinct macrophage population mediates metastatic breast cancer cell extravasation, establishment and growth. PLoS ONE 2009, 4. (e6562).
134. Qian B.Z., Pollard J.W. Macrophage diversity enhances tumor progression and metastasis. Cell 2010, 141:39-51.
135. Quail D.F., Joyce J.A. Microenvironmental regulation of tumor progression and metastasis. Nat Med 2013, 19:1423-1437.
136. Ratushny V., Astsaturov I., Burtness B.A., Golemis E.A., Silverman J.S. Targeting EGFR resistance networks in head and neck cancer. Cell Signal 2009, 21:1255-1268.
137. Raza A., Franklin M.J., Dudek A.Z. Pericytes and vessel maturation during tumor angiogenesis and metastasis. Am J Hematol 2010, 85:593-598.
138. Riboldi E., Musso T., Moroni E., Urbinati C., Bernasconi S., Rusnati M., et al. Cutting edge: proangiogenic properties of alternatively activated dendritic cells. J Immunol 2005, 175:2788-2792.
139. Rogers T.L., Holen I. Tumour macrophages as potential targets of bisphosphonates. J Transl Med 2011, 9:177.
140. Santhekadur P.K., Gredler R., Chen D., Siddiq A., Shen X.N., Das S.K., et al. Late SV40 factor (LSF) enhances angiogenesis by transcriptionally up-regulating matrix metalloproteinase-9 (MMP-9). J Biol Chem 2012, 287:3425-3432.
141. Sawanobori Y., Ueha S., Kurachi M., Shimaoka T., Talmadge J.E., Abe J., et al. Chemokine-mediated rapid turnover of myeloid-derived suppressor cells in tumor-bearing mice. Blood 2008, 111:5457-5466.
142. Scapini P., Lapinet-Vera J.A., Gasperini S., Calzetti F., Bazzoni F., Cassatella M.A. The neutrophil as a cellular source of chemokines. Immunol Rev 2000, 177:195-203.
143. Scapini P., Morini M., Tecchio C., Minghelli S., Di Carlo E., Tanghetti E., et al. CXCL1/macrophage inflammatory protein-2-induced angiogenesis in vivo is mediated by neutrophil-derived vascular endothelial growth factor-A. J Immunol 2004, 172:5034-5040.
144. Schruefer R., Lutze N., Schymeinsky J., Walzog B. Human neutrophils promote angiogenesis by a paracrine feedforward mechanism involving endothelial interleukin-8. Am J Physiol Heart Circ Physiol 2005, 288:H1186-H1192.
145. Sennino B., Ishiguro-Oonuma T., Wei Y., Naylor R.M., Williamson C.W., Bhagwandin V., et al. Suppression of tumor invasion and metastasis by concurrent inhibition of c-Met and VEGF signaling in pancreatic neuroendocrine tumors. Cancer Discov 2012, 2:270-287.
146. Shaw J.P., Chuang N., Yee H., Shamamian P. Polymorphonuclear neutrophils promote rFGF-2-induced angiogenesis in vivo. J Surg Res 2003, 109:37-42.
147. Shojaei F., Singh M., Thompson J.D., Ferrara N. Role of Bv8 in neutrophil-dependent angiogenesis in a transgenic model of cancer progression. Proc Natl Acad Sci U S A 2008, 105:2640-2645.
148. Shojaei F., Wu X., Malik A.K., Zhong C., Baldwin M.E., Schanz S., et al. Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells. Nat Biotechnol 2007, 25:911-920.
149. Sithu S.D., English W.R., Olson P., Krubasik D., Baker A.H., Murphy G., et al. Membrane-type 1-matrix metalloproteinase regulates intracellular adhesion molecule-1 (ICAM-1)-mediated monocyte transmigration. J Biol Chem 2007, 282:25010-25019.
150. Smith H.A., Kang Y. The metastasis-promoting roles of tumor-associated immune cells. J Mol Med (Berl) 2013, 91:411-429.
151. Sounni N.E., Devy L., Hajitou A., Frankenne F., Munaut C., Gilles C., et al. MT1-MMP expression promotes tumor growth and angiogenesis through an up-regulation of vascular endothelial growth factor expression. FASEB J 2002, 16:555-564.
152. Sounni N.E., Roghi C., Chabottaux V., Janssen M., Munaut C., Maquoi E., et al. Up-regulation of vascular endothelial growth factor-A by active membrane-type 1 matrix metalloproteinase through activation of Src-tyrosine kinases. J Biol Chem 2004, 279:13564-13574.
153. Sparmann A., Bar-Sagi D. Ras-induced interleukin-8 expression plays a critical role in tumor growth and angiogenesis. Cancer Cell 2004, 6:447-458.
154. Stockmann C., Doedens A., Weidemann A., Zhang N., Takeda N., Greenberg J.I., et al. Deletion of vascular endothelial growth factor in myeloid cells accelerates tumorigenesis. Nature 2008, 456:814-818.
155. Taguchi A., Kawana K., Tomio K., Yamashita A., Isobe Y., Nagasaka K., et al. Matrix metalloproteinase (MMP)-9 in cancer-associated fibroblasts (CAFs) is suppressed by omega-3 polyunsaturated fatty acids in vitro and in vivo. PLoS ONE 2014, 9. (e89605).
156. Takahashi Y., Bucana C.D., Cleary K.R., Ellis L.M. p53, vessel count, and vascular endothelial growth factor expression in human colon cancer. Int J Cancer 1998, 79:34-38.
157. Takahashi Y., Kitadai Y., Bucana C.D., Cleary K.R., Ellis L.M. Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res 1995, 55:3964-3968.
158. Tan K.W., Chong S.Z., Wong F.H., Evrard M., Tan S.M., Keeble J., et al. Neutrophils contribute to inflammatory lymphangiogenesis by increasing VEGF-A bioavailability and secreting VEGF-D. Blood 2013, 122:3666-3677.
159. Tazawa H., Okada F., Kobayashi T., Tada M., Mori Y., Une Y., et al. Infiltration of neutrophils is required for acquisition of metastatic phenotype of benign murine fibrosarcoma cells: implication of inflammation-associated carcinogenesis and tumor progression. Am J Pathol 2003, 163:2221-2232.
160. Tazzyman S., Lewis C.E., Murdoch C. Neutrophils: key mediators of tumour angiogenesis. Int J Exp Pathol 2009, 90:222-231.
161. Tazzyman S., Niaz H., Murdoch C. Neutrophil-mediated tumour angiogenesis: subversion of immune responses to promote tumour growth. Semin Cancer Biol 2013, 23:149-158.
162. Tressel S.L., Kaneider N.C., Kasuda S., Foley C., Koukos G., Austin K., et al. A matrix metalloprotease-PAR1 system regulates vascular integrity, systemic inflammation and death in sepsis. EMBO Mol Med 2011, 3:370-384.
163. Ugarte-Berzal E., Redondo-Munoz J., Eroles P., Del Cerro M.H., Garcia-Marco J.A., Terol M.J., et al. VEGF/VEGFR2 interaction down-regulates matrix metalloproteinase-9 via STAT1 activation and inhibits B chronic lymphocytic leukemia cell migration. Blood 2010, 115:846-849.
164. Valastyan S., Weinberg R.A. Tumor metastasis: molecular insights and evolving paradigms. Cell 2011, 147:275-292.
165. Van den Steen P.E., Proost P., Wuyts A., Van Damme J., Opdenakker G. Neutrophil gelatinase B potentiates interleukin-8 tenfold by aminoterminal processing, whereas it degrades CTAP-III, PF-4, and GRO-alpha and leaves RANTES and MCP-2 intact. Blood 2000, 96:2673-2681.
166. Vempati P., Mac Gabhann F., Popel A.S. Quantifying the proteolytic release of extracellular matrix-sequestered VEGF with a computational model. PLoS ONE 2010, 5. (e11860).
167. Wang S., Liu H., Ren L., Pan Y., Zhang Y. Inhibiting colorectal carcinoma growth and metastasis by blocking the expression of VEGF using RNA interference. Neoplasia 2008, 10:399-407.
168. Warren R.S., Yuan H., Matli M.R., Gillett N.A., Ferrara N. Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis. J Clin Invest 1995, 95:1789-1797.
169. Waugh D.J., Wilson C. The interleukin-8 pathway in cancer. Clin Cancer Res 2008, 14:6735-6741.
170. Weis S.M., Cheresh D.A. Tumor angiogenesis: molecular pathways and therapeutic targets. Nat Med 2011, 17:1359-1370.
171. Welti J., Loges S., Dimmeler S., Carmeliet P. Recent molecular discoveries in angiogenesis and antiangiogenic therapies in cancer. J Clin Invest 2013, 123:3190-3200.
172. Woenne E.C., Lederle W., Zwick S., Palmowski M., Krell H., Semmler W., et al. MMP inhibition blocks fibroblast-dependent skin cancer invasion, reduces vascularization and alters VEGF-A and PDGF-BB expression. Anticancer Res 2010, 30:703-711.
173. Xue C., Wyckoff J., Liang F., Sidani M., Violini S., Tsai K.L., et al. Epidermal growth factor receptor overexpression results in increased tumor cell motility in vivo coordinately with enhanced intravasation and metastasis. Cancer Res 2006, 66:192-197.
174. Yang E., Boire A., Agarwal A., Nguyen N., O'Callaghan K., Tu P., et al. Blockade of PAR1 signaling with cell-penetrating pepducins inhibits Akt survival pathways in breast cancer cells and suppresses tumor survival and metastasis. Cancer Res 2009, 69:6223-6231.
175. Yao C., Lin Y., Chua M.S., Ye C.S., Bi J., Li W., et al. Interleukin-8 modulates growth and invasiveness of estrogen receptor-negative breast cancer cells. Int J Cancer 2007, 121:1949-1957.
176. Yu W., Chen L., Yang Y.Q., Falck J.R., Guo A.M., Li Y., et al. Cytochrome P450 omega-hydroxylase promotes angiogenesis and metastasis by upregulation of VEGF and MMP-9 in non-small cell lung cancer. Cancer Chemother Pharmacol 2011, 68:619-629.
177. Zajac E., Schweighofer B., Kupriyanova T.A., Juncker-Jensen A., Minder P., Quigley J.P., et al. Angiogenic capacity of M1- and M2-polarized macrophages is determined by the levels of TIMP-1 complexed with their secreted proMMP-9. Blood 2013, 122:4054-4067.
178. Zaynagetdinov R., Sherrill T.P., Polosukhin V.V., Han W., Ausborn J.A., McLoed A.G., et al. A critical role for macrophages in promotion of urethane-induced lung carcinogenesis. J Immunol 2011, 187:5703-5711.
179. Zeisberger S.M., Odermatt B., Marty C., Zehnder-Fjallman A.H., Ballmer-Hofer K., Schwendener R.A. Clodronate-liposome-mediated depletion of tumour-associated macrophages: a new and highly effective antiangiogenic therapy approach. Br J Cancer 2006, 95:272-281.
180. Zhang G., Miyake M., Lawton A., Goodison S., Rosser C.J. Matrix metalloproteinase-10 promotes tumor progression through regulation of angiogenic and apoptotic pathways in cervical tumors. BMC Cancer 2014, 14:310.
181. Zhang J.L., Chen G.W., Liu Y.C., Wang P.Y., Wang X., Wan Y.L., et al. Secreted protein acidic and rich in cysteine (SPARC) suppresses angiogenesis by down-regulating the expression of VEGF and MMP-7 in gastric cancer. PLoS ONE 2012, 7. (e44618).
182. Zhang W., Zhu X.D., Sun H.C., Xiong Y.Q., Zhuang P.Y., Xu H.X., et al. Depletion of tumor-associated macrophages enhances the effect of sorafenib in metastatic liver cancer models by antimetastatic and antiangiogenic effects. Clin Cancer Res 2010, 16:3420-3430.
183. Zhao Y., Xiao A., diPierro C.G., Carpenter J.E., Abdel-Fattah R., Redpath G.T., et al. An extensive invasive intracranial human glioblastoma xenograft model: role of high level matrix metalloproteinase 9. Am J Pathol 2010, 176:3032-3049.
184. Zheng H., Takahashi H., Murai Y., Cui Z., Nomoto K., Niwa H., et al. Expressions of MMP-2, MMP-9 and VEGF are closely linked to growth, invasion, metastasis and angiogenesis of gastric carcinoma. Anticancer Res 2006, 26:3579-3583.
185. Zijlstra A., Seandel M., Kupriyanova T.A., Partridge J.J., Madsen M.A., Hahn-Dantona E.A., et al. Proangiogenic role of neutrophil-like inflammatory heterophils during neovascularization induced by growth factors and human tumor cells. Blood 2006, 107:317-327.